Company / Capital Expenditures
Corvus Pharmaceuticals, Inc. Capital Expenditures History
FY2015-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$34.0K
FY2023
5-year range
$5.0K / $269.0K
FY2019-FY2023
Trend
-87.4%
vs FY2022
Sector context
#180 of 192
Health Care
What the data says
Among 192 Health Care companies, Corvus Pharmaceuticals, Inc. is in the bottom 6% for capital expenditures. Capital Expenditures has fluctuated over the past 9 years, ranging from $5,000 in FY2021 to $2M in FY2016.
Based on SEC 10-K filings.
$34,000 in FY2023 with a 5-year CAGR of -37.4%.
Improved from $5,000 to $34,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -23.5%
- 5-Year CAGR
- -37.4%
- 10-Year CAGR
- -
Sector benchmark
Bottom 6% in Health CareTop 94% of 192This company $34.0K Sector average $118.6M
▼
-100.0% below sector average
Key checks
Key Insights
- 5-year CAGR of -37.4%, indicating a declining trend.
- In FY2023, capital expenditures decreased 87.4% year-over-year.
- Ranks #180 out of 192 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | $34.0K | -87.4% |
| FY2022 | $269.0K | +5280.0% |
| FY2021 | $5.0K | -93.4% |
| FY2020 | $76.0K | +204.0% |
| FY2019 | $25.0K | -93.0% |
| FY2018 | $355.0K | +33.5% |
| FY2017 | $266.0K | -87.9% |
| FY2016 | $2.2M | +25.9% |
| FY2015 | $1.7M | - |
As of FY2023 · SEC 10-K · Updated Feb 28, 2026